IN2012DN03448A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03448A
IN2012DN03448A IN3448DEN2012A IN2012DN03448A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A IN 3448DEN2012 A IN3448DEN2012 A IN 3448DEN2012A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A
Authority
IN
India
Prior art keywords
compounds
methods
administration
preparing
disclosed
Prior art date
Application number
Inventor
Hallock Ebetino Frank
Wieslaw Mazur Adam
Lee Martin Dobson Roy
Original Assignee
Warner Chilcott Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co Llc filed Critical Warner Chilcott Co Llc
Publication of IN2012DN03448A publication Critical patent/IN2012DN03448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.
IN3448DEN2012 2009-10-26 2010-10-26 IN2012DN03448A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25488609P 2009-10-26 2009-10-26
PCT/US2010/054124 WO2011056589A1 (en) 2009-10-26 2010-10-26 Bisphosphonate compounds for treating bone metabolism disorders

Publications (1)

Publication Number Publication Date
IN2012DN03448A true IN2012DN03448A (en) 2015-10-23

Family

ID=43478185

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3448DEN2012 IN2012DN03448A (en) 2009-10-26 2010-10-26

Country Status (10)

Country Link
US (3) US8314081B2 (en)
EP (1) EP2493905B1 (en)
JP (1) JP5850842B2 (en)
CN (1) CN102630227B (en)
CA (1) CA2778015C (en)
IL (1) IL219235A (en)
IN (1) IN2012DN03448A (en)
MX (1) MX2012004769A (en)
SG (1) SG10201406846XA (en)
WO (1) WO2011056589A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2778015C (en) 2009-10-26 2016-08-02 Warner Chilcott Company, Llc Bisphosphonate compounds for treating bone metabolism disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
KR20200137035A (en) * 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 Biguanide compositions and methods of treating metabolic disorders
JP2017512183A (en) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド Prodrug compounds and their use
CN106687118A (en) * 2014-07-02 2017-05-17 配体药物公司 Prodrug compounds and uses thereof
RU2020126177A (en) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. ACETAL COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2043072B (en) * 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
DE3640938A1 (en) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS COMPOUND
JPH0699457B2 (en) * 1988-08-12 1994-12-07 山之内製薬株式会社 Heterocyclic bisphosphonic acid derivative and its medicine
US4990503A (en) 1988-08-12 1991-02-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic bisphosphonic acid derivatives
US5039699A (en) * 1989-03-27 1991-08-13 Lederle (Japan), Ltd. Anti-peptic ulcer agent
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI89366C (en) * 1990-12-20 1993-09-27 Leiras Oy PROCEDURE FOR THE FRAMEWORK OF THE PHARMACOLOGICAL PROCEDURE OF METHYLENBISPHOSPHONYRADERIVAT
US5157027A (en) * 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
DE69224830D1 (en) * 1991-06-19 1998-04-23 Upjohn Co Dialkyl (dialkoxyphosphinyl)methyl phosphate als antientzündungsmittel
JPH05239075A (en) * 1991-08-27 1993-09-17 Eisai Co Ltd Phosphorus-containing isoprenoid derivative
JPH06172372A (en) * 1991-11-06 1994-06-21 Takeda Chem Ind Ltd Squalene synthetase inhibitor and its use
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
JP3526575B2 (en) * 1993-03-08 2004-05-17 エーザイ株式会社 Phosphonic acid derivatives
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
EP0705834A1 (en) 1994-07-27 1996-04-10 Ciba-Geigy Ag Quinoxaline-2,3-diones with an azaheterocyclic fused ring
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
EP1802641B8 (en) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7781418B2 (en) 2006-12-14 2010-08-24 Isis Innovation Ltd. Composition for treating bone disorders
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
EP2344503B1 (en) 2008-09-22 2014-04-16 Isis Innovation Ltd 5-azaindole bisphosphonates
KR20110079813A (en) 2008-09-22 2011-07-08 아이시스 이노베이션 리미티드 Imidazo [1,2-α] pyridinyl bisphosphonate
CA2778015C (en) 2009-10-26 2016-08-02 Warner Chilcott Company, Llc Bisphosphonate compounds for treating bone metabolism disorders

Also Published As

Publication number Publication date
JP2013508459A (en) 2013-03-07
EP2493905A1 (en) 2012-09-05
US20110098251A1 (en) 2011-04-28
IL219235A0 (en) 2012-06-28
US8314081B2 (en) 2012-11-20
CN102630227B (en) 2016-03-23
US20140194389A1 (en) 2014-07-10
WO2011056589A1 (en) 2011-05-12
US8822435B2 (en) 2014-09-02
MX2012004769A (en) 2012-08-08
CN102630227A (en) 2012-08-08
US8710215B2 (en) 2014-04-29
IL219235A (en) 2017-01-31
CA2778015C (en) 2016-08-02
EP2493905B1 (en) 2016-11-30
CA2778015A1 (en) 2011-05-12
US20130035482A1 (en) 2013-02-07
SG10201406846XA (en) 2014-12-30
JP5850842B2 (en) 2016-02-03

Similar Documents

Publication Publication Date Title
IN2014DN09805A (en)
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2012DN02735A (en)
IN2012DN00754A (en)
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
EA201290482A1 (en) STABLE COMPOSITIONS FOR LIOPHILIZATION OF THERAPEUTIC PARTICLES
IN2014DN09804A (en)
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2011007930A (en) Crystalline insulin-conjugates.
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
MX343135B (en) Fumagillol type compounds and methods of making and using same.
MY155564A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
MX2012001660A (en) Linaclotide-containing formulations for oral administration.
IN2012DN03448A (en)
MX2012001134A (en) Compositions and methods for inhibition of the jak pathway.
WO2011023367A3 (en) Bisphosphonate-prodrugs
BR112012026098A2 (en) methods and compositions for improving implant osseointegration.
MX357284B (en) Quinone compounds for treating ape1 mediated diseases.
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX342119B (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
MX2009011577A (en) Compositions and methods for transmucosal delivery of domperidone.
WO2011147034A8 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof